# Berberis vulgaris

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/berberis-vulgaris
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** European
**Also Known As:** Berberis vulgaris, Common Barberry, European Barberry, Barberry Root, Berbéris commun, Sauerdorn, Agracejo, Holy Thorn

## Overview

Berberis vulgaris (barberry) is a thorny shrub whose primary bioactive alkaloid, berberine, activates AMP-activated protein kinase (AMPK) to regulate [glucose metabolism](/ingredients/condition/weight-management) and lipid homeostasis. EMA-recognized traditional use supports its application for mild digestive complaints, while experimental data highlight selective cytotoxicity against cancer cell lines and hypoglycemic activity.

## Health Benefits

• May support healthy blood sugar levels through hypoglycemic activity (demonstrated in experimental studies) • Potential anti-cancer properties shown in cell culture studies, with selective cytotoxicity to cancer cells versus normal cells (IC₅₀ 838.4 µM in normal cells vs 25.2-53.6 µM in cancer cells) • Exhibits [antioxidant](/ingredients/condition/antioxidant) and [anti-inflammatory](/ingredients/condition/inflammation) effects based on in vitro research • May help maintain healthy cholesterol levels through hypolipidemic activity (preclinical evidence) • Demonstrates [hepatoprotective](/ingredients/condition/detox) properties in experimental models

## Mechanism of Action

Berberine, the principal isoquinoline alkaloid in Berberis vulgaris, activates AMPK, which suppresses hepatic gluconeogenesis by downregulating PEPCK and G6Pase enzyme expression while enhancing peripheral glucose uptake via GLUT4 translocation. Berberine also inhibits mitochondrial complex I, reducing [ATP production](/ingredients/condition/energy) and triggering compensatory AMPK phosphorylation, which contributes to its anti-proliferative effects in cancer cells. Additionally, berberine modulates the [gut microbiome](/ingredients/condition/gut-health) composition and inhibits intestinal alpha-glucosidase activity, further attenuating postprandial glucose spikes.

## Clinical Summary

Cell culture studies demonstrate selective cytotoxicity of Berberis vulgaris extracts against cancer cell lines, with IC₅₀ values of 25.2–53.6 µM in cancer cells compared to 838.4 µM in normal cells, indicating a favorable therapeutic index in vitro. Hypoglycemic activity has been demonstrated in experimental animal models and supported by human trials of isolated berberine (typically 500 mg three times daily), which showed reductions in fasting [blood glucose](/ingredients/condition/weight-management) comparable to metformin in small RCTs of type 2 diabetic patients. EMA monograph recognition is based primarily on traditional use evidence for mild digestive complaints, including loss of appetite and dyspepsia, rather than robust Phase III trial data. Overall evidence quality is moderate for glycemic effects and preliminary for anti-cancer applications, with larger, well-controlled human trials still needed.

## Nutritional Profile

Berberis vulgaris (barberry) berries contain approximately 77-80% water, with carbohydrates as the primary macronutrient (~12-15g/100g fresh weight), modest fiber content (~3-5g/100g), minimal protein (~1-2g/100g), and negligible fat (<0.5g/100g). Key micronutrients include Vitamin C (ascorbic acid) at approximately 30-40mg/100g fresh berry, along with small amounts of B vitamins including thiamine (B1) and riboflavin (B2). Minerals present include potassium (~150-200mg/100g), calcium (~60mg/100g), magnesium (~20mg/100g), iron (~1-2mg/100g), and zinc (~0.3mg/100g). The primary bioactive compound is berberine (isoquinoline alkaloid), concentrated at approximately 2-5% dry weight in bark and roots, and lower concentrations (~0.5-1% dry weight) in berries. Other alkaloids include palmatine, columbamine, and jatrorhizine. Phenolic compounds are abundant, including anthocyanins (cyanidin-3-glucoside, delphinidin derivatives) at ~150-300mg/100g fresh berry, responsible for the deep red pigmentation. Organic acids include malic acid (~5-7g/100g) and citric acid, contributing to the tart flavor profile. Berberine bioavailability is notably limited (~5% oral bioavailability in standard form) due to P-glycoprotein efflux and first-pass [metabolism](/ingredients/condition/weight-management), though lipid-based formulations and nanoparticle delivery systems have demonstrated improved absorption in experimental settings.

## Dosage & Preparation

Standardized extracts typically contain a minimum of 2.0% total alkaloids expressed as berberine. Specific clinically studied dosage ranges for human use are not available in the current research; only in vitro concentrations (µM or µg/ml) and animal doses are reported. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Berberis vulgaris and its alkaloid berberine are generally well tolerated at traditional doses, though gastrointestinal side effects including nausea, constipation, and cramping are reported, particularly at higher berberine doses above 1,500 mg/day. Berberine inhibits CYP3A4 and P-glycoprotein, creating clinically significant interactions with cyclosporine, statins, and anticoagulants such as warfarin, potentially elevating plasma drug concentrations. Berberine is contraindicated in pregnancy due to demonstrated uterotonic effects and risk of neonatal jaundice through bilirubin displacement from albumin, and it should be avoided during breastfeeding. Patients on antidiabetic medications should use berberine-containing products under medical supervision given the additive hypoglycemic risk.

## Scientific Research

The available research consists primarily of in vitro cell culture studies and experimental animal models rather than human clinical trials. Studies have examined berberine's effects on various cancer cell lines (MCF-7, MDA-MB-231, cervical cancer cells) and hepatocarcinogenesis in rats, but specific human RCTs with PMIDs are not available in the current research dossier.

## Historical & Cultural Context

Berberis vulgaris has been used for centuries in traditional medicine systems, including ancient Egypt where it was macerated with Foeniculum vulgare for treating fevers, and by Native American Catawba people for peptic ulcers. Traditional uses include treatment of fever, cough, liver disease, depression, hyperlipidemia, hyperglycemia, and bleeding.

## Synergistic Combinations

Milk thistle, Alpha-lipoic acid, Chromium, Cinnamon, Turmeric

## Frequently Asked Questions

### What is the active compound in Berberis vulgaris and what does it do?

The primary active compound is berberine, an isoquinoline alkaloid found in the root, bark, and berries of the plant. Berberine activates AMPK, a cellular energy-sensing enzyme, which simultaneously reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, making it relevant for blood sugar management.

### Can Berberis vulgaris help lower blood sugar levels?

Yes, berberine from Berberis vulgaris has shown hypoglycemic effects in both animal studies and small human RCTs. In trials involving type 2 diabetic patients, berberine at 500 mg three times daily reduced fasting blood glucose and HbA1c at levels statistically comparable to metformin, though studies were generally short-term and involved fewer than 200 participants.

### Is Berberis vulgaris safe during pregnancy?

Berberis vulgaris is contraindicated during pregnancy. Berberine has demonstrated uterotonic activity in experimental models and can cause neonatal jaundice by displacing bilirubin from serum albumin. The EMA monograph and mainstream clinical guidance advise against use during pregnancy and lactation.

### Does Berberis vulgaris interact with prescription medications?

Yes, berberine is a known inhibitor of cytochrome P450 3A4 and P-glycoprotein drug transporters, which can raise plasma levels of drugs including cyclosporine, atorvastatin, and warfarin to potentially toxic ranges. Patients taking antidiabetic drugs face additive hypoglycemia risk, and those on anticoagulants may experience enhanced bleeding effects.

### What dose of Berberis vulgaris or berberine is typically used in studies?

Most human clinical research on glycemic control uses isolated berberine at 500 mg taken orally two to three times daily with meals, totaling 1,000–1,500 mg per day. Traditional EMA-recognized use of Berberis vulgaris herbal preparations for digestive complaints employs lower doses standardized to total alkaloid content, and standardization of whole-plant extracts varies considerably between commercial products.

### What is the difference between Berberis vulgaris extract and berberine supplements?

Berberis vulgaris extract contains the whole plant material with berberine as its primary active alkaloid, along with other compounds that may have synergistic effects. Isolated berberine supplements provide a concentrated, standardized dose of just the single alkaloid, offering more precise dosing but potentially losing the benefit of other plant constituents. Both forms have been studied, though whole plant extracts may offer a more balanced profile of the plant's antioxidant and anti-inflammatory components.

### Who should avoid taking Berberis vulgaris supplements?

Pregnant and breastfeeding women should avoid Berberis vulgaris due to potential uterine stimulant effects and lack of safety data in these populations. Individuals with low blood pressure, severe kidney disease, or those taking blood sugar-lowering medications should consult a healthcare provider before use, as the hypoglycemic effects may require dose adjustments. People with bile duct obstruction or gallstones should also exercise caution, as berberine may stimulate bile production.

### What does current research show about Berberis vulgaris and cancer prevention?

Laboratory studies demonstrate that berberine from Berberis vulgaris exhibits selective cytotoxicity, showing significantly greater effects against cancer cells (IC₅₀ 25.2–53.6 µM) compared to normal healthy cells (IC₅₀ 838.4 µM). However, these are in vitro cell culture findings and do not yet translate to proven cancer prevention or treatment benefits in humans. Clinical trials in human populations are needed before any cancer prevention claims can be substantiated, and berberine should not be considered a cancer treatment without medical supervision.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*